Effects of Cannabis Species Labeling and Marketing on Perceptual, Subjective and Objective Use Outcomes
- Institution
- Johns Hopkins University, MD
- Principal investigator
- Meghan Bridgid Moran
- Funding
- $721K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Sale of cannabis for recreational use is rapidly becoming legal across states in the US. While cannabis use policies typically contain marketing restrictions, including prohibitions on misleading marketing claims, there is limited research to inform operationalization of these policies, and these policies are rarely enforced. Cannabis products are often labeled based on “species” or cultivar (Indica, Sativa, or Hybrid). Notably, there is limited evidence that different species consistently have different profiles of chemical constituents. Despite this, cannabis is marketed directly to consumers with product labels “Indica”, “Sativa”, and “Hybrid”, and with corresponding marketing claims that the product has sedative (e.g., relaxation, sleepiness) or energizing (e.g., focus, productivity, physical activity) effects. Consumers also report experiencing sedative effects from Indica- labeled cannabis and energizing effects from Sativa-labeled cannabis. This may translate into unsafe use: our prior work has found consumers are more likely to report using Sativa-labeled (vs. Indica-labeled) cannabis before driving or going to work. Despite the potential for public health harm, there is no data demonstrating whether product perceptions, use expectancies, and subjective and objective acute effects of use vary by label or marketing claim. Research from other consumer domains, including tobacco, indicates that labeling and marketing can have powerful effects on product perceptions, use behavior, and use experience. Marketing and labeling for cannabis could similarly foster inaccurate product perceptions (e.g., regarding harm), expectancy effects (e.g., anticipating a product to increase focus) and lead to unsafe use (e.g., while driving). This undermines initiatives to promote safe use of cannabis and risks public health. To date, controlled research has not systematically evaluated how product labeling (Indica, Sativa, Hybrid) or associated marketing claims (sedative vs. energizing) affect use behavior, risk perception, or acute drug effects. The proposed research uses a large-scale content analysis of cannabis labeling and marketing (Aim 1), a randomized online experiment (Aim 2), and a placebo-controlled randomized laboratory experiment (Aim 3) to document the scope and effects of cannabis labeling (Indica, Sativa, Hybrid) and marketing claims (sedative, energizing). Ultimately, this work will provide evidence to inform cannabis marketing and labeling policies, which are necessary to protect public health.
Research team
- Meghan Bridgid MoranPI
- Carlos Austin ZamarripaPI
LOADING MOONBASE SCORE
Questions for Johns Hopkins University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Johns Hopkins UniversityNot yet scored
From Perceptions to Behaviors: A Comprehensive Approach to Examine the Impact of Public Health Communication Messaging about the Continuum of Risk for Tobacco Products
Meghan Bridgid Moran · $2.4M · 2024–2028
- NIH · Johns Hopkins University72
Development, Piloting and Dissemination of an Integrated Clinical and Social Multi-level Decision Support Platform to Address Social Determinants of Health Among Minority Populations in Baltimore City
Elham Hatef-Naimi · $611K · 2021–2025
- NIH · Johns Hopkins University66
Glucose instability and neurocognitive outcomes in older adults
Elizabeth Selvin · $697K · 2021–2027